Follow
Chimeric antigens
Antigens are foreign substances that induce the body to generate an immune response and produce antibodies. The better the immune system can recognize antigens, the more effective immune response it can mount. Chimeric antigens are specially engineered proteins that designed to improve the ability of immune cells to target a specific disease-associated antigen.
-
NOV 07, 2017 | 10:00 AM
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...OCT 26, 2017 | 12:00 PM
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...OCT 19, 2017 | 8:00 AM
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...OCT 19, 2017 | 8:00 AM
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...OCT 05, 2016 | 10:30 AM
The immune system possesses significant cytotoxic potential. Stimulating natural immunity through vaccination has shown promising effects in some cancers; however, a number of barriers limit...Speaker: Michael Milone, PhD
NOV 07, 2017 | 10:00 AM
DATE: November 7, 2017 TIME: 10:00AM PSTChimeric Antigen Receptor (CAR)-transduced T lymphocytes have demonstrated impressive clinical activity against B cell malignancies in...
OCT 26, 2017 | 12:00 PM
DATE: October 26, 2017TIME: 12:00 PM PDTThis presentation will focus on recent advances in cellular therapy—from mesenchymal stromal cells (MSCs) to tumor-specific T-cells. More s...
OCT 19, 2017 | 8:00 AM
DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
OCT 19, 2017 | 8:00 AM
Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T c...
OCT 05, 2016 | 10:30 AM
The immune system possesses significant cytotoxic potential. Stimulating natural immunity through vaccination has shown promising effects in some cancers; however, a number of barriers limit...
Speaker:
Michael Milone, PhD